INS and obesity due to melanocortin 4 receptor deficiency: Semaglutide, which is approved for managing T2D and obesity, works by enhancing insulin secretion, thereby reducing glucagon release, lowering blood glucose levels, and suppressing appetite, leading to weight loss [34].